There has been an increasing prevalence of leprosy after receiving the COVID-19 vaccination, with 49 out of the 52 people – 98 percent – transferred to the specialist Leprosy Clinic at the Hospital for Tropical Diseases in London (HTD) in 2021 being referred after the vaccine.
HTD undertook two case studies of people that matched the definition of an adverse reaction involving leprosy, whereby within 12 weeks of receiving the vaccine, someone developed the disease despite having no previous diagnoses or connections. One individual developed “borderline tuberculoid leprosy” a week after the second jab and the other within two months of a COVID-19 vaccine dose.
The coronavirus vaccines have been found to provoke a response from white blood cells or T-cells, which are capable of triggering Mycobacterium leprae, a bacteria that causes leprosy – a disease curiously also on the rise in Florida.
The study warned that clinicians take the connection into account, stating: “It is important for clinicians to be aware of the potential leprosy adverse events associated with SARS-CoV-2 vaccination.”
The vaccine has been linked with a number of other adverse effects, including menstrual disturbances among women, untreatable eyeball clots, and myocarditis.
